p53 accumulation in ovarian carcinomas and its prognostic implications

Silvano Bosari, Giuseppe Viale, Umberto Radaelli, Paola Bossi, Emanuela Bonoldi, Guido Coggi

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Intranuclear p53 accumulation is a common finding in many different human tumors and is associated with a worse prognosis in breast, colon, and lung carcinomas. We immunostained a series of common epithelial ovarian cancers to assess (1) the prevalence of p53 accumulation and its clinicopathologic correlations, and (2) its prognostic implications. The study population comprised 98 patients (83 with follow-up data). A variable degree of p53 immunoreactivity, strictly confined to the neoplastic cells, was detected in 54 tumors (55%). Among these tumors there were 10 low expressors (1% to 10% immunoreactive tumor cells), 16 moderate expressors (10% to 50% immunoreactive cells), and 28 high expressors (>50% immunoreactive cells). The prevalence of p53 immunoreactivity did not show any association with the histologic type of the tumors or with the disease stage at presentation. p53 Accumulation, however, was significantly more prevalent among poorly differentiated tumors (P = .0059, by analysis of variance). Life table analysis demonstrated that patients with tumors showing moderate and high p53 expression had worse disease-free and adjusted lengths of survival (P = .0011 and P = .0025, respectively, by Mantel-Cox). The patients with "early stage" disease (stages I and II) and p53 accumulation showed a trend toward shorter length of survival, but this did not reach statistical significance. However, patients with "advanced stage" disease (stages III and IV) and moderate or high p53 accumulation had a poorer prognosis (P = .0154 and P = .0171, for disease-free and adjusted length of survival, respectively). These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.

Original languageEnglish
Pages (from-to)1175-1179
Number of pages5
JournalHuman Pathology
Volume24
Issue number11
DOIs
Publication statusPublished - 1993

Fingerprint

Carcinoma
Neoplasms
Survival
Life Tables
Analysis of Variance
Colon
Breast
Lung
Population

Keywords

  • immunocytochemistry
  • ovarian carcinoma
  • p53
  • prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

p53 accumulation in ovarian carcinomas and its prognostic implications. / Bosari, Silvano; Viale, Giuseppe; Radaelli, Umberto; Bossi, Paola; Bonoldi, Emanuela; Coggi, Guido.

In: Human Pathology, Vol. 24, No. 11, 1993, p. 1175-1179.

Research output: Contribution to journalArticle

Bosari, Silvano ; Viale, Giuseppe ; Radaelli, Umberto ; Bossi, Paola ; Bonoldi, Emanuela ; Coggi, Guido. / p53 accumulation in ovarian carcinomas and its prognostic implications. In: Human Pathology. 1993 ; Vol. 24, No. 11. pp. 1175-1179.
@article{c48862d772c64f3292d6687918cfb37c,
title = "p53 accumulation in ovarian carcinomas and its prognostic implications",
abstract = "Intranuclear p53 accumulation is a common finding in many different human tumors and is associated with a worse prognosis in breast, colon, and lung carcinomas. We immunostained a series of common epithelial ovarian cancers to assess (1) the prevalence of p53 accumulation and its clinicopathologic correlations, and (2) its prognostic implications. The study population comprised 98 patients (83 with follow-up data). A variable degree of p53 immunoreactivity, strictly confined to the neoplastic cells, was detected in 54 tumors (55{\%}). Among these tumors there were 10 low expressors (1{\%} to 10{\%} immunoreactive tumor cells), 16 moderate expressors (10{\%} to 50{\%} immunoreactive cells), and 28 high expressors (>50{\%} immunoreactive cells). The prevalence of p53 immunoreactivity did not show any association with the histologic type of the tumors or with the disease stage at presentation. p53 Accumulation, however, was significantly more prevalent among poorly differentiated tumors (P = .0059, by analysis of variance). Life table analysis demonstrated that patients with tumors showing moderate and high p53 expression had worse disease-free and adjusted lengths of survival (P = .0011 and P = .0025, respectively, by Mantel-Cox). The patients with {"}early stage{"} disease (stages I and II) and p53 accumulation showed a trend toward shorter length of survival, but this did not reach statistical significance. However, patients with {"}advanced stage{"} disease (stages III and IV) and moderate or high p53 accumulation had a poorer prognosis (P = .0154 and P = .0171, for disease-free and adjusted length of survival, respectively). These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.",
keywords = "immunocytochemistry, ovarian carcinoma, p53, prognosis",
author = "Silvano Bosari and Giuseppe Viale and Umberto Radaelli and Paola Bossi and Emanuela Bonoldi and Guido Coggi",
year = "1993",
doi = "10.1016/0046-8177(93)90212-Y",
language = "English",
volume = "24",
pages = "1175--1179",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - p53 accumulation in ovarian carcinomas and its prognostic implications

AU - Bosari, Silvano

AU - Viale, Giuseppe

AU - Radaelli, Umberto

AU - Bossi, Paola

AU - Bonoldi, Emanuela

AU - Coggi, Guido

PY - 1993

Y1 - 1993

N2 - Intranuclear p53 accumulation is a common finding in many different human tumors and is associated with a worse prognosis in breast, colon, and lung carcinomas. We immunostained a series of common epithelial ovarian cancers to assess (1) the prevalence of p53 accumulation and its clinicopathologic correlations, and (2) its prognostic implications. The study population comprised 98 patients (83 with follow-up data). A variable degree of p53 immunoreactivity, strictly confined to the neoplastic cells, was detected in 54 tumors (55%). Among these tumors there were 10 low expressors (1% to 10% immunoreactive tumor cells), 16 moderate expressors (10% to 50% immunoreactive cells), and 28 high expressors (>50% immunoreactive cells). The prevalence of p53 immunoreactivity did not show any association with the histologic type of the tumors or with the disease stage at presentation. p53 Accumulation, however, was significantly more prevalent among poorly differentiated tumors (P = .0059, by analysis of variance). Life table analysis demonstrated that patients with tumors showing moderate and high p53 expression had worse disease-free and adjusted lengths of survival (P = .0011 and P = .0025, respectively, by Mantel-Cox). The patients with "early stage" disease (stages I and II) and p53 accumulation showed a trend toward shorter length of survival, but this did not reach statistical significance. However, patients with "advanced stage" disease (stages III and IV) and moderate or high p53 accumulation had a poorer prognosis (P = .0154 and P = .0171, for disease-free and adjusted length of survival, respectively). These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.

AB - Intranuclear p53 accumulation is a common finding in many different human tumors and is associated with a worse prognosis in breast, colon, and lung carcinomas. We immunostained a series of common epithelial ovarian cancers to assess (1) the prevalence of p53 accumulation and its clinicopathologic correlations, and (2) its prognostic implications. The study population comprised 98 patients (83 with follow-up data). A variable degree of p53 immunoreactivity, strictly confined to the neoplastic cells, was detected in 54 tumors (55%). Among these tumors there were 10 low expressors (1% to 10% immunoreactive tumor cells), 16 moderate expressors (10% to 50% immunoreactive cells), and 28 high expressors (>50% immunoreactive cells). The prevalence of p53 immunoreactivity did not show any association with the histologic type of the tumors or with the disease stage at presentation. p53 Accumulation, however, was significantly more prevalent among poorly differentiated tumors (P = .0059, by analysis of variance). Life table analysis demonstrated that patients with tumors showing moderate and high p53 expression had worse disease-free and adjusted lengths of survival (P = .0011 and P = .0025, respectively, by Mantel-Cox). The patients with "early stage" disease (stages I and II) and p53 accumulation showed a trend toward shorter length of survival, but this did not reach statistical significance. However, patients with "advanced stage" disease (stages III and IV) and moderate or high p53 accumulation had a poorer prognosis (P = .0154 and P = .0171, for disease-free and adjusted length of survival, respectively). These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.

KW - immunocytochemistry

KW - ovarian carcinoma

KW - p53

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=0027331811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027331811&partnerID=8YFLogxK

U2 - 10.1016/0046-8177(93)90212-Y

DO - 10.1016/0046-8177(93)90212-Y

M3 - Article

C2 - 8244317

AN - SCOPUS:0027331811

VL - 24

SP - 1175

EP - 1179

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -